SIGA Shares Fall 13% As Monkeypox Cases Decline Globally

Dow Jones2022-08-26

By Kathryn Hardison

 

Shares of SIGA Technologies Inc. slid Thursday after the World Health Organization said the number of monkeypox cases reported globally fell last week.

At 2:32 p.m. ET, shares were down 13% at $18.21 after falling as low as $17.89 during the day.

SIGA's Tpoxx drug has been used as a treatment thought to be effective against monkeypox. U.S. officials has made the drug available for seriously ill patients using its stockpile of 1.7 million treatment courses that it acquired in the event of a smallpox outbreak, The Wall Street Journal reported.

Monkeypox is a virus that is mainly infecting men in the U.S. and other countries who have sex with men.

The health agency said Thursday that there was a continued steep rise in cases in the region of the Americas last week, while the number of cases globally fell 21%.

More than 41,000 cases of monkeypox and 12 deaths have been reported from 96 countries, according to a WHO report that was updated Thursday.

SIGA's Tpoxx was approved in the U.S. to treat smallpox in 2018 and hasn't been approved for monkeypox, making it difficult for infected patients to get it, the Journal reported. The U.S. is unlikely to authorize Tpoxx formally for monkeypox before it reviews human study data, which could be seen by the end of the year.

 

Write to Kathryn Hardison at kathryn.hardison@wsj.com

$(END)$ Dow Jones Newswires

August 25, 2022 14:51 ET (18:51 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment